Search

Displaying results 5681 - 5690 of 7604 in total
  1. Drug

    Sodium borate

    go.drugbank.com/drugs/DB14505
    Approved

  2. Drug

    Melaleuca alternifolia leaf

    go.drugbank.com/drugs/DB14372
    Investigational

    Melaleuca alternifolia leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Pimplepatch By Glam Up
  3. Drug

    Pyrrobutamine

    go.drugbank.com/drugs/DB13846
    Experimental

    Categories: Antihistamines for Systemic Use
  4. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol is being investigated for the treatment of thrombotic thrombocytopenic purpura and acute coronary syndromes. … Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets.

  5. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    UCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. … [A254222] Plasmepsins are aspartyl proteases produced by the malaria parasite _Plasmodium falciparum_, and PMX is considered to be essential for parasite egress and invasion.

  6. Drug

    Pentaerithrityl

    go.drugbank.com/drugs/DB13526
    Investigational

    Categories: Drugs for Constipation
  7. Drug

    Carrimycin

    go.drugbank.com/drugs/DB16476
    Investigational

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  9. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  10. Drug

    QR-334

    go.drugbank.com/drugs/DB05473
    Experimental

    QR-334 is under investigation for the treatment of sialorrhea. Sialorrhea is an excess secretion of saliva produced by the salivary glands, resulting in drooling.